FrancophonIA/ELRC3.0 huggingface dataset:
English: Pharmacotherapeutic group: Corticosteroids, dermatological preparations.
Croatian: Farmakoterapijska grupa: kortikosteroidi, dermatološki pripravci ATCvet kod: QD07AC16
English: Clear colourless to slightly yellow solution.
Croatian: Bistra bezbojna do svijetložuta otopina.
English: Hydrocortisone aceponate applications on the skin lesions provide rapid reduction of the skin redness, irritation and scratching while minimising the general effects.
Croatian: Nanošenje hidrokortizon aceponata na oštećenja kože omogućava brzo umanjenje crvenila, nadražaja i svrbeži dok su opći učinci minimalni.
English: Hydrocortisone aceponate belongs to the diesters class of the glucocorticosteroids.
Croatian: HCA pripada diesterskoj skupini glukokortikoida.
English: Name and address of the manufacturer responsible for batch release
Croatian: Naziv i adresa proizvođača odgovornog za otpuštanje serije u promet
English: Bioglan AB Borrgatan 31 211 24 Malmo Sweden
Croatian: SE-21124 Malmö Sweden
English: SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Croatian: 13. POSEBNE MJERE PREDOSTROŽNOSTI ZA ODLAGANJE NEUPOTREBLJENOG PROIZVODA ILI OTPADNIH MATERIJALA, AKO IH
English: This dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a square of 10 cm x 10 cm. Repeat the treatment daily for 7 consecutive days.
Croatian: Ova se doza postiže s dvije aktivacije sprej pumpice na površinu koju treba tretirati, ekvivalentnu kvadratu od 10 x 10 cm.
English: PSUR submissions shall be synchronised and submitted at the same frequency as for the reference product.
Croatian: Specifični zahtjevi farmakovigilancije: PSUR-evi će se podnositi istovremeno i jednako često kao i za referentni VMP.
English: PHARMACEUTICAL FORM Cutaneous spray, solution.
Croatian: OBLIK Sprej za kožu, otopina.
English: THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN” Keep out of the sight and reach of children.
Croatian: 11. POSEBNE MJERE PREDOSTROŽNOSTI ZA ČUVANJE Čuvati izvan pogleda i dosega djece.
English: METHOD AND ROUTE(S) OF ADMINISTRATION Cutaneous use.
Croatian: NAČIN I PUT(EVI) PRIMJENE
English: Prime the pump before administration.
Croatian: Pripremite pumpicu prije primjene.
English: D. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING
Croatian: DRUGI UVJETI ILI OGRANIČENJA ODOBRENJA ZA STAVLJANJE U PROMET
English: Pregnancy and lactation:
Croatian: Primjena tijekom graviditeta, laktacije ili nesenja
English: Active substance
Croatian: NAVOĐENJE DJELATNIH TVARI
English: STATEMENT OF ACTIVE SUBSTANCES Each ml contains 0.584 mg of hydrocortisone aceponate.
Croatian: Svaki ml sadrži 0,584 mg hidrokortizon aceponata.
English: In case of accidental eye contact, rinse with abundant quantities of water.
Croatian: U slučaju da do njega dođe, isprati s većim količinama vode.
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Cortacare 0.584 mg/ml cutaneous spray solution for dogs hydrocortisone aceponate
Croatian: NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Cortacare 0,584 mg/ml sprej za kožu otopina za pse hidrokortizon aceponat
English: Special warnings for each target species:
Croatian: 12. POSEBNO(A) UPOZORENJE(A) Posebna upozorenja za svaku od ciljnih vrsta životinja
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGE OUTER CARTON
Croatian: PODACI NA VANJSKOM PAKOVANJU
English: NAME OF THE VETERINARY MEDICINAL PRODUCT Cortacare 0.584 mg/ml cutaneous spray solution for dogs.
Croatian: NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Cortacare 0,584 mg/ml sprej za kožu otopina za pse
English: 4.9 Amounts to be administered and administration route
Croatian: 4.9 Količine koje se primjenjuju i način primjene Za kožu.
English: STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Hydrocortisone aceponate 0.584 mg/ml.
Croatian: NAVOĐENJE DJELATNE(IH) TVARI I DRUGIH SASTOJAKA Hidrokortizon aceponat 0,584 mg/ml Bistra bezbojna do svijetložuta otopina.
English: Special precautions for storage Do not store above 25oC.
Croatian: Nemojte čuvati pri temperaturi iznad 25 °C
English: ADVERSE REACTIONS
Croatian: Djelatna tvar
English: PACKAGE LEAFLET: Cortacare 0.584 mg/ml cutaneous spray solution for dogs
Croatian: UPUTA O VMP Cortacare 0,584 mg/ml, sprej za kožu, otopina za pse
English: Cutaneous use.
Croatian: Hidrokortizon aceponat
English: Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.
Croatian: O načinu na koji možete odložiti ili ukloniti ovaj veterinarsko-medicinski proizvod, upitajte vašeg veterinara.
English: It is used in adults for the following:
Croatian: Primjenjuje se u odraslih osoba za:
English: The full EPAR for Inhixa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Inhixa nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The safety profiles of the two medicines were also considered similar, based on laboratory testing.
Croatian: Sigurnosni profili tih dvaju lijekova također se smatraju sličnima na temelju laboratorijskog ispitivanja.
English: This helps to stop the formation of new blood clots and control existing ones.
Croatian: To pridonosi zaustavljanju nastanka novih krvnih ugrušaka i kontroli postojećih.
English: This means that Inhixa is highly similar to a biological medicine (also known as the ‘reference medicine') that is already authorised in the European Union (EU).
Croatian: Drugim riječima, Inhixa je slična biološkom lijeku (poznatom kao „referentni lijek“) koji je već odobren u Europskoj uniji (EU).
English: Enoxaparin sodium
Croatian: Enoksaparin natrij
English: • to treat certain types of myocardial infarction (heart attack);
Croatian: • liječenje određenih vrsta infarkta miokarda (srčanog udara);
English: The dose and how long the medicine is given for, as well as whether it is given with other medicines, depend on the condition to be prevented or treated.
Croatian: Doziranje i trajanje liječenja, kao i potreba uzimanja u kombinaciji s drugim lijekovima, ovisi o bolesti koju je potrebno spriječiti ili liječiti.
English: Other information about Inhixa
Croatian: Ostale informacije o lijeku Inhixa
English: What measures are being taken to ensure the safe and effective use of Inhixa?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Inhixa?
English: Doses must be adjusted in patients with severely reduced kidney function.
Croatian: Potrebno je prilagoditi doze u bolesnika s teško oštećenom funkcijom bubrega.
English: Therefore, the Agency's Committee for Medicinal Products for Human Use (CHMP) considered that there are no clinically meaningful differences between Inhixa and Clexane in terms of effectiveness and safety and took the view that, as for Clexane, the benefit outweighs the identified risk.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji stoga je zaključio da ne postoje klinički značajne razlike između lijekova Inhixa i Clexane u pogledu djelotvornosti i sigurnosti te smatra da, kao i za lijek Clexane, koristi nadmašuju identificirani rizik.
English: What is Inhixa and what is it used for?
Croatian: Što je Inhixa i za što se koristi?
English: Enoxaparin increases the effect of antithrombin III, a natural substance that controls the blood's clotting factors and helps prevent blood from clotting inside the body.
Croatian: Enoksaparin pojačava učinak antitrombina III, prirodne tvari koja kontrolira faktore zgrušavanja krvi i pomaže u sprječavanju zgrušavanja krvi unutar tijela.
English: In addition, a study in 20 healthy subjects has shown the same doses of the two products given by injection under the skin produced similar effects on blood clotting factors, using various measures that reflect the way the medicine works in the body.
Croatian: Nadalje, ispitivanje na 20 zdravih ispitanika pokazalo je da jednake doze tih dvaju proizvoda primijenjenih supkutanom injekcijom uzrokuju slične učinke na faktore zgrušavanja krvi, primjenom različitih mjerila koja odražavaju način na koji lijek djeluje u tijelu.
English: When blood clots develop inside blood vessels they may restrict the blood flow to the organs, including the heart.
Croatian: Krvni ugrušci koji nastaju unutar krvnih žila mogu ograničiti protok krvi u organe, uključujući srce.
English: The company also provided information from published studies showing the benefits of enoxaparin in preventing and treating blood clots.
Croatian: Tvrtka je također pružila informacije iz objavljenih ispitivanja koje dokazuju koristi enoksaparina u sprječavanju i liječenju krvnih ugrušaka.
English: What are the risks associated with Inhixa?
Croatian: Koji su rizici povezani s lijekom Inhixa?
English: • to prevent clots forming when blood is circulated through a haemodialysis machine to remove toxic substances.
Croatian: • sprječavanje nastanka ugrušaka kada krv cirkulira kroz uređaj za hemodijalizu radi uklanjanja otrovnih tvari.
English: The Committee recommended that Inhixa be given marketing authorisation.
Croatian: Odbor je preporučio izdavanje odobrenja za stavljanje lijeka Inhixa u promet.
English: This is a summary of the European public assessment report (EPAR) for Inhixa.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije o lijeku (EPAR) za lijek Inhixa.
English: Inhixa is a ‘biosimilar medicine'.
Croatian: Inhixa je „biosličan lijek”.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Inhixa have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Inhixa nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: It is usually given as an injection under the skin although in the treatment of a type of heart attack called acute ST-segment elevation myocardial infarction (STEMI) it is first given as an injection into a vein, and to prevent clots in haemodialysis machines it is injected directly into the tube carrying the blood.
Croatian: Obično se primjenjuje u obliku supkutane injekcije, iako se pri liječenju jedne vrste srčanog udara naziva akutni infarkt miokarda s elevacijom ST-spojnice (STEMI) prvo primjenjuje u obliku intravenske injekcije, dok se za sprječavanje ugrušaka u uređajima za hemodijalizu ubrizgava izravno u cijev koja prenosi krv.
English: It is not intended to provide practical advice on how to use Inhixa.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Inhixa.
English: The active substance in Inhixa, enoxaparin, is one of a group of anticoagulant medicines called ‘low-molecular weight heparins'.
Croatian: Djelatna tvar lijeka Inhixa, enoksaparin, pripada skupini antikoagulansa naziva „heparini niske molekularne težine”.
English: The most common side effect with Inhixa (which may affect more than 1 in 10 people) is haemorrhage (bleeding); serious bleeding occurred in around 4 people in 100 given Inhixa to prevent blood clots during surgery.
Croatian: Najčešća nuspojava lijeka Inhixa (koja se može javiti u više od 1 na 10 osoba) je krvarenje; do ozbiljnog krvarenja došlo je u oko 4 na 100 osoba koje su primile lijek Inhixa radi sprječavanja krvnih ugrušaka tijekom kirurškog zahvata.
English: For more information about treatment with Inhixa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Inhixa pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: Why is Inhixa approved?
Croatian: Zašto je lijek Inhixa odobren?
English: Extensive laboratory studies comparing Inhixa with Clexane have shown that Inhixa is highly similar to Clexane in terms of structure, purity and biological activity.
Croatian: Opsežna laboratorijska ispitivanja u kojima je lijek Inhixa uspoređen s lijekom Clexane pokazala su da postoji velika sličnost između njih u pogledu strukture, čistoće i biološke aktivnosti.
English: • to prevent venous thromboembolism (blood clots that form inside the veins, obstructing blood flow), especially in patients who are having surgery or who are at greater risk of clots because they are bedridden due to illness;
Croatian: • sprječavanje venske tromboembolije (krvni ugrušci koji nastaju unutar vena i sprječavaju protok krvi), naročito u bolesnika koji idu na kirurški zahvat ili su izloženi većem riziku od nastanka ugrušaka jer su zbog bolesti prikovani uz krevet;
English: The reference medicine for Inhixa is Clexane.
Croatian: Referentni lijek za Inhixu je Clexane.
English: Inhixa is available as a solution for injection in pre-filled syringes.
Croatian: Lijek Inhixa dostupan je kao otopina za injekciju u napunjenim štrcaljkama.
English: • to treat conditions associated with blood clots such as deep vein thrombosis (where the clot develops in a deep vein, usually in the leg);
Croatian: • liječenje bolesti povezanih s krvnim ugrušcima poput duboke venske tromboze (pri kojoj krvni ugrušak nastaje u dubokoj veni, obično u nozi);
English: Inhixa must not be used in patients with existing major bleeding, severe disorders of blood clotting, or with conditions that increase the risk of, or from, bleeding, such as stomach ulcers or stroke.
Croatian: Lijek Inhixa ne smije se primjenjivati u bolesnika s postojećim većim krvarenjem, ozbiljnim poremećajima zgrušavanja krvi ili bolestima koje povećavaju rizik od krvarenja, kao što su čir na želucu ili moždani udar.
English: • to treat unstable angina (a severe type of chest pain caused by problems with the blood flow to the heart);
Croatian: • liječenje nestabilne angine pektoris (ozbiljnog oblika boli u prsima uzrokovane problemima s protokom krvi do srca);
English: Studies have shown that Inhixa has a highly similar structure and biological activity to Clexane and has the same effect on blood clotting factors.
Croatian: Ispitivanja su pokazala da lijek Inhixa ima veoma sličnu strukturu i biološku aktivnost u usporedbi s lijekom Clexane te da ima jednak učinak na faktore zgrušavanja krvi.
English: For practical information about using Inhixa, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Inhixa bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: In the treatment of unstable angina and heart attack Inhixa is given with aspirin (acetylsalicylic acid).
Croatian: Inhixa se pri liječenju nestabilne angine pektoris i infarkta miokarda primjenjuje u kombinaciji s aspirinom (acetilsalicilnom kiselinom).
English: What benefits of Inhixa have been shown in studies?
Croatian: Koje su koristi lijeka Inhixa dokazane u ispitivanjima?
English: Inhixa is an anticoagulant medicine (a medicine to prevent blood clots).
Croatian: Inhixa je antikoagulans (lijek za sprječavanje nastanka krvnih ugrušaka).
English: How does Inhixa work?
Croatian: Kako djeluje Inhixa?
English: In addition, increased levels of liver enzymes in the blood (a sign of possible liver problems) are very common (may affect more than 1 in 10 people).
Croatian: Nadalje, veoma su česte (mogu se javiti u više od 1 na 10 osoba) povišene razine jetrenih enzima u krvi (znak mogućih problema s jetrom).
English: For the full list of all side effects reported with Inhixa, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Inhixa potražite u uputi o lijeku.
English: How is Inhixa used?
Croatian: Kako se Inhixa koristi?
English: The active substance in Inhixa is enoxaparin sodium.
Croatian: Djelatna tvar lijeka Inhixa je enoksaparin natrij.
English: This was recorded in two questionnaires completed at home.
Croatian: To je zabilježeno u dva upitnika koja su ispitanici popunjavali kod kuće.
English: • patients who have hypotension (low blood pressure);
Croatian: • bolesnici koji imaju hipotenziju (nizak krvni tlak);
English: • patients who have had a stroke or a heart attack within the last six months;
Croatian: • bolesnici koji su imali moždani udar ili srčani udar unutar posljednjih šest mjeseci;
English: The European Commission granted a marketing authorisation valid throughout the European Union for Vivanza on 4 March 2003.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Vivanza vrijedi na prostoru Europske unije od 4. ožujka 2003.
English: This summary was last updated in 01-2016.
Croatian: Sažetak je posljednji put ažuriran: 01.2016.
English: The main measure of effectiveness was the ability to get and maintain an erection.
Croatian: Glavno mjerilo učinkovitosti bila je mogućnost postizanja i održavanja erekcije.
English: The recommended dose of Vivanza is 10 mg, taken by mouth with or without food, about 25 to 60 minutes before sexual activity; patients should not take more than one dose a day.
Croatian: Preporučena doza lijeka Vivanza je 10 mg, uzeta na usta s hranom ili bez nje, otprilike 25 do 60 minuta prije seksualne aktivnosti; bolesnici ne bi smjeli uzeti više od jedne doze dnevno.
English: The dose may be increased to a maximum of 20 mg or decreased to 5 mg depending on the effectiveness and side effects.
Croatian: Doza se može povećati na najviše 20 mg ili smanjiti na 5 mg, ovisno o učinkovitosti i nuspojavama.
English: Vivanza was significantly more effective than placebo for all measures in all studies.
Croatian: Lijek Vivanza bio je znatno djelotvorniji od placeba u pogledu svih mjerila u svim ispitivanjima.
English: It must not be used when sexual activity is inadvisable, such as in men with severe heart disease.
Croatian: Lijek se ne smije koristiti u slučaju kad se seksualne aktivnosti ne preporučuju, kao što je slučaj kod muškaraca s teškom bolesti srca.
English: Because Vivanza has not been studied in the following groups of patients, they must not use the medicine:
Croatian: S obzirom da lijek Vivanza nije ispitivan u sljedećim skupinama bolesnika, sljedeće skupine ne smiju koristiti lijek:
English: What measures are being taken to ensure the safe and effective use of Vivanza?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Vivanza?
English: It is available as film-coated tablets (5, 10 and 20 mg) and as orodispersible tablets (10 mg).
Croatian: Lijek je dostupan u obliku filmom obloženih tableta (5, 10 i 20 mg) i u obliku orodisperzibilnih tableta (10 mg).
English: Two additional main studies compared orodispersible tablets with placebo in 701 men aged 21 to 84 years.
Croatian: Dva dodatna glavna ispitivanja usporedila su raspadljive tablete za usta s placebom kod 701 muškarca u dobi od 21 do 84 godine.
English: Vivanza is used to treat adult men with erectile dysfunction (sometimes called impotence), when they cannot get, or keep, a hard penis (erection) sufficient for satisfactory sexual activity.
Croatian: Vivanza se koristi za liječenje odraslih muškaraca s erektilnom disfunkcijom (koja se ponekad naziva impotencija), kada ne mogu postići ili održati ukrućeni penis (erekciju) dostatan za zadovoljavajuću seksualnu aktivnost.
English: The most common side effect with Vivanza (seen in more than 1 patient in 10) is headache.
Croatian: Najčešća nuspojava lijeka Vivanza (uočena kod više od 1 na 10 bolesnika) je glavobolja.
English: Patients with liver problems or severe kidney problems should start treatment on the 5 mg dose.
Croatian: Bolesnici koji imaju probleme s jetrom ili teške probleme s bubrezima trebaju započeti liječenje dozom od 5 mg.
English: Other information about Vivanza
Croatian: Ostale informacije o lijeku Vivanza
English: If Vivanza is taken with a high fat meal, the onset of activity may be delayed.
Croatian: Ako se Vivanza uzima s obrokom koji sadrži puno masnoće, početak djelovanja može biti odgođen.
English: The dose may need to be adjusted in patients taking other medicines that block enzymes that break down Vivanza.
Croatian: Možda će biti potrebno prilagoditi dozu kod bolesnika koji uzimaju druge lijekove koji blokiraju enzime potrebne za razgradnju lijeka Vivanza.
English: This is a summary of the European public assessment report (EPAR) for Vivanza.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Vivanza.
English: For Vivanza to be effective, sexual stimulation is required.
Croatian: Kako bi Vivanza bila djelotvorna, potrebna je seksualna stimulacija.
English: The orodispersible tablets must be taken without liquid.
Croatian: Raspadljive tablete za usta moraju se uzeti bez tekućine.
English: Orodispersible tablets are tablets that dissolve in the mouth.
Croatian: Orodisperzibilne tablete su raspadljive tablete za usta.
English: This allows blood to flow into the corpora, producing the erection.
Croatian: To omogućava dotok krvi u kavernozna tijela, što dovodi do erekcije.
English: A risk management plan has been developed to ensure that Vivanza is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Vivanza.
English: • patients with unstable angina or hereditary eye problems known as ‘retinal degenerative disorders'.
Croatian: • bolesnici s nestabilnom anginom ili nasljednim očnim problemima poznatima kao „degenerativne promjene mrežnice”.
English: By blocking the breakdown of cGMP, Vivanza restores erectile function.
Croatian: Blokadom razgradnje cGMP-a Vivanza ponovno uspostavlja erektilnu funkciju.
English: Vivanza film-coated tablets have been compared with placebo (a dummy treatment) in four main studies including 2,431 men aged 20 to 83 years.
Croatian: Filmom obložene tablete Vivanza uspoređene su s placebom (prividno liječenje) u četiri glavna ispitivanja koja su uključivala 2431 muškarca u dobi od 20 do 83 godine.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vivanza.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka Vivanza.
English: Vivanza is a medicine that contains the active substance vardenafil.
Croatian: Vivanza je lijek koji sadrži djelatnu tvar vardenafil.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Vivanza, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Vivanza nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: What is the risk associated with Vivanza?
Croatian: Koji su rizici povezani s lijeka Vivanza?
English: Vivanza must not be taken with some medicines, such as ketoconazole and itraconazole (to treat fungal infections) in men over 75 years, or medicines called ‘HIV protease inhibitors' such as ritonavir or indinavir (to treat HIV infection).
Croatian: Lijek Vivanza ne smije se uzimati s nekim lijekovima poput ketokonazola i itrakonazola (za liječenje gljivičnih infekcija) u muškaraca starijih od 75 godina ili lijekova zvanih „inhibitori HIV proteaze” poput ritonavira ili indinavira (za liječenje infekcije HIV-om).
English: The active ingredient of Vivanza, vardenafil, belongs to a group of medicines called phosphodiesterase type 5 (PDE5) inhibitors.
Croatian: Vardenafil, djelatni sastojak lijeka Vivanza, pripada skupini lijekova zvanih inhibitori fosfodiesteraze tipa 5 (PDE5).
English: During normal sexual stimulation, cGMP is produced in the penis, where it causes the muscle in the spongy tissue of the penis (the corpora cavernosa) to relax.
Croatian: Tijekom normalne seksualne stimulacije u penisu se stvara cGMP i uzrokuje opuštanje mišića spužvastog tkiva penisa (corpora cavernosa).